Tech Company Financing Transactions

Adaptive Biotechnologies Funding Round

Adaptive Biotechnologies secured a $195 million financing round on 5/6/2015. Investors included Matrix Capital Management, Alexandria Venture Investments and Casdin Capital.

Transaction Overview

Announced On
5/6/2015
Transaction Type
Venture Equity
Amount
$195,000,000
Round
Undisclosed
Proceeds Purpose
This investment will fuel significant expansion of the Company's research platform, support the commercialization of a novel target identification technology for T-cell therapy, and expedite global regulatory submissions and launch timelines for its research-use-only and clinical diagnostic products. Additionally, funds will be allocated to support the continued growth of the world's largest database of adaptive immune receptors to inform future diagnostic and therapeutic discoveries across disease states.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1551 Eastlake Ave. East 200
Seattle, WA 98102
USA
Email Address
Overview
Adaptive (Nasdaq: ADPT) is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
Profile
Adaptive Biotechnologies LinkedIn Company Profile
Social Media
Adaptive Biotechnologies Company Twitter Account
Company News
Adaptive Biotechnologies News
Facebook
Adaptive Biotechnologies on Facebook
YouTube
Adaptive Biotechnologies on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Chad Robins
  Chad Robins LinkedIn Profile  Chad Robins Twitter Account  Chad Robins News  Chad Robins on Facebook
Chief Financial Officer
Chad Cohen
  Chad Cohen LinkedIn Profile  Chad Cohen Twitter Account  Chad Cohen News  Chad Cohen on Facebook
Chief Technical Officer
Sean Nolan
  Sean Nolan LinkedIn Profile  Sean Nolan Twitter Account  Sean Nolan News  Sean Nolan on Facebook
Co-Founder
Harlan Robins
  Harlan Robins LinkedIn Profile  Harlan Robins Twitter Account  Harlan Robins News  Harlan Robins on Facebook
Founder
Christopher Carlson
  Christopher Carlson LinkedIn Profile  Christopher Carlson Twitter Account  Christopher Carlson News  Christopher Carlson on Facebook
VP - Bus. Development
Julie Rubinstein
  Julie Rubinstein LinkedIn Profile  Julie Rubinstein Twitter Account  Julie Rubinstein News  Julie Rubinstein on Facebook
VP - General Counsel
Gene DeFelice
  Gene DeFelice LinkedIn Profile  Gene DeFelice Twitter Account  Gene DeFelice News  Gene DeFelice on Facebook
VP - Operations
Nancy Hill
  Nancy Hill LinkedIn Profile  Nancy Hill Twitter Account  Nancy Hill News  Nancy Hill on Facebook
VP - Regulatory Affairs
Melina Cimler
  Melina Cimler LinkedIn Profile  Melina Cimler Twitter Account  Melina Cimler News  Melina Cimler on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/6/2015: Moximed venture capital transaction
Next: 5/6/2015: DrFirst venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary